Lisata Therapeutics’ (LSTA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a research note published on Thursday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Separately, Brookline Capital Management increased their target price on Lisata Therapeutics from $20.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.50.

Lisata Therapeutics Price Performance

Shares of LSTA opened at $2.47 on Thursday. Lisata Therapeutics has a 1 year low of $1.87 and a 1 year high of $4.20. The company has a 50 day simple moving average of $2.62 and a two-hundred day simple moving average of $2.46. The firm has a market cap of $21.64 million, a P/E ratio of -1.11 and a beta of 0.93.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $0.07 million for the quarter. On average, sell-side analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

Several hedge funds have recently bought and sold shares of the business. Cerity Partners LLC purchased a new stake in shares of Lisata Therapeutics in the 2nd quarter worth $32,000. Citadel Advisors LLC bought a new position in shares of Lisata Therapeutics in the 4th quarter worth $69,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Lisata Therapeutics by 45.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,226 shares of the company’s stock worth $75,000 after acquiring an additional 7,886 shares in the last quarter. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.